We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
BioMarin Pharmaceutical Inc | NASDAQ:BMRN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-1.80 | -2.15% | 82.00 | 80.55 | 105.00 | 84.80 | 82.32 | 84.80 | 1,632,894 | 05:00:10 |
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 8, 2019
BioMarin Pharmaceutical Inc.
(Exact name of Registrant as Specified in Its Charter)
Delaware | 000-26727 | 68-0397820 | ||
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
||
770 Lindaro Street, San Rafael, California | 94901 | |||
(Address of Principal Executive Offices) | (Zip Code) |
Registrants Telephone Number, Including Area Code: (415) 506-6700
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
☐ |
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
||
Common Stock, $.001 par value | BMRN | The Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On July 8, 2019, the Board of Directors (the Board) of BioMarin Pharmaceutical Inc. (the Company), increased the size of the Board from ten to eleven members and appointed Elizabeth Anderson to the Board, effective July 15, 2019. The Board has not yet appointed Ms. Anderson to any Board committees or determined the Board committees upon which she may serve in the future.
As an independent director, Ms. Anderson is entitled to receive the standard director fees paid to the Companys independent directors and retainer fees paid to members of any Board committees on which she may sit, as described in the Companys Definitive Proxy Statement on Schedule 14A (the Proxy Statement), filed with the Securities and Exchange Commission (the SEC) on April 23, 2019.
In connection with her appointment to the Board, on July 9, 2019, Ms. Anderson was granted 4,490 restricted stock units (the RSU Grant) pursuant to the Companys 2017 Equity Incentive Plan, as amended, representing a pro rata share of the 2019 annual award for independent directors. The shares of common stock subject to the RSU Grant will vest on June 4, 2020, the same vesting date for the 2019 annual award for all other independent directors.
The Company also intends to enter into an indemnification agreement with Ms. Anderson in the same form as the Companys standard form indemnification agreement with its other directors, which is attached as Exhibit 10.1 to the Companys Current Report on Form 8-K, filed with the SEC on December 19, 2016.
Ms. Anderson was not selected by the Board to serve as a director pursuant to any arrangement or understanding with any person. Ms. Anderson has not engaged in any transaction that would be reportable as a related party transaction under Item 404(a) of Regulation S-K.
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
BioMarin Pharmaceutical Inc., a Delaware corporation |
||||||
Date: July 10, 2019 | By: | /s/ G. Eric Davis | ||||
G. Eric Davis | ||||||
Executive Vice President, General Counsel |
-3-
1 Year BioMarin Pharmaceutical Chart |
1 Month BioMarin Pharmaceutical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions